The administration of the catecholamine inhibitors methyltyrosine (MTP) or atrial natriuretic peptide (ANP) prior to CD19-CAR T cell therapy reduced plasma epinephrine and norepinephrine levels, as well as the plasma levels of IFN-α, TNF-α, and IL-6, and ultimately improved mouse survival without diminishing the expansion and tumor clearance of CAR-Ts [97]. The gene discussed is TNF; the disease is neoplasm.